| Literature DB >> 29299153 |
Fangrong Yan1, Yue Wang1, Chunhui Liu2, Huiling Zhao1, Liya Zhang1, Xiaofan Lu1, Chen Chen1, Yaoyan Wang1, Tao Lu3, Fei Wang1.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most prominent type of kidney cancer in adults. The patients within metastatic ccRCC have a poor 5-year survival rate that is less than 10%. It is essential to identify ccRCC -related genes to help with the understanding of molecular mechanism of ccRCC. In this literature, we aim to identify genes related to ccRCC based on a gene network. We collected gene expression level data of ccRCC from the Cancer Genome Atlas (TCGA) for our analysis. We constructed a co-expression gene network as the first step of our study. Then, the network sparse boosting approach was performed to select the genes which are relevant to ccRCC. Results of our study show there are 15 genes selected from the all genes we collected. Among these genes, 7 of them have been demonstrated to play a key role in development and progression or in drug response of ccRCC. This finding offers clues of gene markers for the treatment of ccRCC.Entities:
Keywords: clear cell renal cell carcinoma; gene expression; gene marker; gene network; gene selection
Year: 2017 PMID: 29299153 PMCID: PMC5746388 DOI: 10.18632/oncotarget.22769
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Analysis of network topology for various soft-thresholding powers
The left panel shows the scale-free fit index (y-axis) as a function of the soft-thresholding power (x-axis). The right panel displays the mean connectivity (degree, y-axis) as a function of the soft-thresholding power (x-axis).
Figure 2The graph for module4 in gene network using Circos software
The links in center of the graph are edges which is greater than 0.5 between genes in the network. The histogram in the circle are the log-foldchange values of differentially expressed genes in network.
Figure 3GO annotation and enrichment plot for (A) module1, (B) module2. The colors of each annotation depict the statistical significance of functional enrichment and the bars show the number of target genes contained in the corresponding annotation.
The differentially expressed results and estimates of 15 selected genes using NSBoosting approach
| Gene | Description | Padja | Log-foldchangeb | Dysregulation formc | Estimatesd | Pre-reportede |
|---|---|---|---|---|---|---|
| long intergenic non-protein coding RNA 896 | 1.96E-02 | 3.6729 | up | -0.1537 | ||
| sushi domain containing 4 | 1.73E-49 | -3.7160 | down | -0.1910 | ||
| major histocompatibility complex, class I, G | 1.20E-20 | 2.5233 | up | 0.1558 | √ | |
| mitochondria localized glutamic acid rich protein | 3.56E-07 | 2.8779 | up | 0.1602 | ||
| spindle and kinetochore associated complex subunit 3 | 1.12E-02 | 2.0727 | up | -0.2614 | ||
| cystin 1 | 3.51E-67 | -2.0583 | down | 0.1817 | ||
| collagen type V alpha 1 chain | 4.17E-05 | 2.2068 | up | 0.2543 | √ | |
| plasminogen activator, urokinase | 4.21E-27 | -2.1804 | down | -0.2805 | √ | |
| glial cell derived neurotrophic factor | 2.70E-02 | -2.0430 | down | -0.2122 | √ | |
| otoancorin | 4.75E-03 | 2.6513 | up | 0.3545 | √ | |
| immunoglobulin-like and fibronectin type III domain containing 1 | 4.33E-02 | 5.6544 | up | -0.1253 | ||
| chromosome 2 open reading frame 40 | 6.17E-08 | -2.2598 | down | 0.1457 | √ | |
| BARX homeobox 2 | 4.19E-42 | 2.5958 | up | 0.2343 | ||
| homeobox B13 | 1.91E-02 | 3.5208 | up | -0.1159 | √ | |
| mucin 12, cell surface associated | 5.97E-05 | 4.0677 | up | -0.1518 |
a Adjusted p-value is calculated in differential expression analysis with threshold of 0.05.
b Log-foldchange is calculated in differential expression analysis with threshold of 2.
c Dysregulation form indicates whether the corresponding gene is up- or down-regulated.
d Estimates of selected genes is calculated in NSBoosting approach.
e That a gene is pre-reported means some ccRCC-relevant research has been done before.
Figure 4Kaplan-Meier (KM) survival curves for (A) 7 genes and (B) 8 genes. KM survival curves show significant overall survival differences between higher-expression levels and lower-expression levels of ccRCC patients.